Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 12 of 12 for “"everolimus"”.
-
Characterization of Everolimus In Biodegradable PLAF/PLEOF Nanoparticle
… surfactant-free encapsulation and delivery of Everolimus from DES. Elution of Everolimus was measured from Poly (lactide-fumarate)(PLAF) and Poly (lactide-co-ethylene oxide fumarate))(PLEOF) nanoparticle. Synthesis of the 90%PLAF/10%PLEOF NPs and characterization with respect to particle size …
-
The study of a drug coating applied using a cold atmospheric plasma: everolimus coating properties
… active pharmaceutical ingredients (APIs) such as everolimus is commonly used for therapeutic purposes such as reducing inflammatory responses and preventing restenosis in cardiovascular stents. Traditional coating methods like dipping and spraying require lengthy drying and curing steps, which may …
-
Einfluss der Immunsuppressiva Cyclosporin A und Everolimus auf die funktionelle DNA-Reparaturfähigkeit sowie auf die Regulation von DNA-Reparatur-Genen
Cyclosporin A verursacht im Gegensatz zu Everolimus ein dramatisch erhöhtes Hautkrebsrisiko bei Transplantationspatienten. Die molekulargenetische Wirkung von Cyclosporin A, welche über eine immunsuppressive Wirkung hinauszugehen scheint, ist weitgehend unerforscht. Auch Xeroderma Pigmentosum (XP-) …
-
A Phase I Dose-Escalation Study of The Braf Inhibitor Vemurafenib In Combination With The Mtor Inhibitor Everolimus In Subjects With Advanced Cancer
… profile of the combination of vemurafenib and everolimus will be well tolerated. The primary objective is to find the maximum tolerated dose (MTD) and the toxicity of the combination of vemurafenib and everolimus following a standard 3 + 3 design. The most common diagnosis was melanoma in 5 out …
-
Συστηματική ανασκόπηση της αποτελεσματικότητας και της ασφάλειας του Giredestrant στη θεραπεία του καρκίνου του μαστού - Systematic review on the efficacy and safety of Giredestrant for breast cancer therapy
… επιβίωσης χωρίς εξέλιξη νόσου με giredestrant + everolimus έναντι exemestane + everolimus μετά από πρόοδο υπό CDK4/6-αναστολείς. Τρεις επιπλέον μελέτες φάσης III (lidERA BC, persevERA BC, pionERA BC) βρίσκονται σε εξέλιξη. Το giredestrant ήταν γενικώς καλά ανεκτό, με τις περισσότερες ανεπιθύμητες …
-
MOLECULAR MECHANISMS UNDERLYING CLINICAL BEHAVIOR OF NEUROENDOCRINE TUMORS: STUDY OF NEW POSSIBLE BIOMARKERS PREDICTABLE OF PHARMACOLOGICAL RESISTANCE AND TARGETS
… DAs, and that combined therapy with DAs avoids everolimus escape feed-back in PitNETs. The role of -arrestin 2 in regulating both AKT phosphorylation and cell proliferation in tumoral lactotrophs and NF-PitNETs was demonstrated, elucidating a new molecular mechanism that contributes to confer …
-
The Kras/Mapk Pathway and Ligand Independent Activation of Erα: Implications For The Treatment of Endometrial Cancer
… evaluate the effect of treatment with letrozole, everolimus, and metformin <em>in vivo</em>. These studies demonstrated that tumors with an activating KRas mutation are resistant to treatment with letrozole even in combination with everolimus. Tumor growth and cellular proliferation were reduced …
-
INVESTIGATING MECHANISMS REGULATING MAMMALIAN SPERMATOGONIAL DIFFERENTIATION AND MEIOTIC INITIATION
… In chapter 2, I describe negative effects of Everolimus, a pharmaceutical compound commonly used to treat cancer, on male fertility in mice. In chapter 3, I identify a new fluorescent reporter mouse model used to isolate large, highly enriched, precise population of germ cell at specific …
-
Improved delivery of molecularly targeted agents upon modulation of multidrug resistance efflux proteins at mouse blood brain barrier
… in the treatment regimen. Erlotinib, canertinib, everolimus and temsirolimus were screened as potential modulators of P-gp and Bcrp1 activity. The fact that these drugs inhibit a different class of receptor population than pazopanib and vandetanib, offer a dual advantage for synergistic …
-
Análisis obsevacional para evaluar la eficacia y seguridad de los mTORi en la esfera oncológica en el paciente trasplantado hepático
… appearance of mTOR inhibitors (mTORi, sirolimus, everolimus) within the immunosuppressive arsenal as non-nephrotoxic agents may represent an advance in the tumor control of these patients, since they are basically used in the area of oncology as antiproliferative agents. Objectives: 1): To analyze …